A growing number of Australians prescribed Vyvanse are raising concerns about the drug’s safety and effectiveness. The Therapeutic Goods Administration (TGA) has launched an official investigation into Vyvanse safety concerns Australia-wide, after receiving a surge in adverse event notifications in 2025.
Sudden Rise in Side Effect Reports
Vyvanse, one of the most commonly used medications for Attention Deficit Hyperactivity Disorder (ADHD) in Australia, has seen a massive spike in reports of negative side effects this year. Patients and healthcare professionals have reported symptoms including anxiety, insomnia, and an unexpected reduction in the drug’s effectiveness.
According to a spokesperson from the TGA, the regulator is independently testing Vyvanse batches to assess whether the product quality has changed. Importantly, the manufacturer, Takeda Pharmaceuticals, claims that no changes have been made to the chemical formulation or production methods of Vyvanse.
Investigation Into Possible Quality Issues
The TGA’s investigation includes laboratory testing and a detailed review of recent complaints. The watchdog confirmed there are currently no compliance issues at the production facilities responsible for making Vyvanse. However, the surge in complaints has triggered what is known as a safety signal—a possible pattern of adverse events that warrants further scrutiny.
In addition to concerns over effectiveness and safety, the TGA also noted that 88 reports of labelling issues were submitted. Earlier in the year, the medicine’s packaging was flagged for minor typographical errors, including an extra ‘S’ added to the word “capsule” on some labels: “Each capsules contains 60mg lisdexamfetamine dimesilate.”
What Does This Mean for Patients?
For now, patients taking Vyvanse are advised to continue their medication as prescribed but to report any unusual side effects or issues to their doctor and to the TGA. Healthcare professionals are encouraged to remain vigilant and monitor patients closely for changes in effectiveness or adverse reactions.
The TGA has not yet issued a formal recall or safety alert but will update the public once the investigation concludes. The review is ongoing and will determine whether further regulatory action is necessary.
Vyvanse Remains Approved – For Now
Despite the recent surge in reports, Vyvanse remains an approved medication for ADHD treatment in Australia. The current investigation is precautionary, aiming to ensure that the drug continues to meet Australia’s strict safety and quality standards.
Patients concerned about their medication are urged to consult their healthcare provider before making any changes to their treatment.
